




RealRate

PHARMACEUTICAL 2018

Aimmune Therapeutics Inc
Rank 112 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Aimmune Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aimmune Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 109% points. The greatest weakness of Aimmune Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 29% points.

The company's Economic Capital Ratio, given in the ranking table, is 314%, being 62% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	189,111
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,599
Liabilities, Non-Current	2,530
Other Assets	618
Other Compr. Net Income	-81
Other Expenses	56
Other Liabilities	0
Other Net Income	2,005
Other Revenues	0
Property and Equipment	17,205
Research and Development	89,325
Selling, General and Administrative Expense	43,949

Output Variable	Value in 1000 USD
Assets	206,934
Liabilities	29,129
Expenses	133,330
Revenues	0
Stockholders Equity	177,805
Net Income	-131,325
Comprehensive Net Income	-131,366
BaseVar	185,740
ECR before LimitedLiability	217%
Economic Capital Ratio	314%